Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AlloCure Inc.

www.allocure.com

Latest From AlloCure Inc.

Biopharma Quarterly Deal Statistics, Q2 2012

Follow-on public offerings continued to dominate, with 19 transactions making up almost half of Q2’s $2.7 billion financing volume. M&A dollars, up nearly four times that of Q1, totaled $34.7 billion, for 28 completed transactions, seven of which topped the billion dollar mark. In alliances, the Q2 potential deal value – also largely increased over the previous quarter’s – marked possibly the highest amount ever seen along with maybe the most expensive deal ever: Walgreen $6.6 billion agreement to purchase a minority equity share in Alliance Boots, bringing in over half of Q2’s value.

BioPharmaceutical Deals

Recent Financings Of Private Companies, May 2012

START-UP's comprehensive review of emerging life science companies that have received venture funding during the month, including companies within the in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies sectors.

BioPharmaceutical Medical Device

AlloCure raises $25mn to take lead stem cell therapy into Phase II

AlloCure has raised $25 million in a Series B financing round involving one new investor, Lundbeckfond Ventures, which becomes the second Danish corporate venture fund to invest in the Burlington, Massachusetts-based biotech company.

Orthopedics Denmark

AlloCure Inc.

There are precious few options for addressing acute kidney injury, a condition that is characterized by a rapid deterioration of kidney function, often occurring in people with certain risk factors and co-morbidities. Some 300,000 to 500,000 people each year in the US suffer from AKI. AlloCure Inc. is developing bone marrow-derived adult stem cells harvested from anonymous donors, and prepared as an off-the-shelf therapy, to prevent and perhaps eventually treat AKI.
BioPharmaceutical Regenerative Medicine
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AlloCure Inc.
  • Senior Management
  • Robert M Brenner, MD, Pres. & CEO
    Cristof Westenfeider, MD, CMO
    Kevin J Heyeck, CBO
  • Contact Info
  • AlloCure Inc.
    Phone: (801) 583-8450
    615 Arapeen Dr., Ste. 300
    Salt Lake City, UT 84108
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register